Nebibe Varol
Denham, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer.
Journal: Clinical lung cancer
Published: December 11, 2023
Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey.
Journal: BMC cancer
Published: February 28, 2023
Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 04, 2022
Treatment patterns for advanced non-small cell lung cancer in the US: A systematic review of observational studies.
Journal: Cancer treatment and research communications
Published: June 28, 2022
Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Journal: Journal of medical economics
Published: June 06, 2022
Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Journal: Journal of medical economics
Published: June 06, 2022
Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 24, 2022
Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 14, 2019
Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK.
Journal: International journal of chronic obstructive pulmonary disease
Published: September 15, 2018
Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States.
Journal: Journal of medical economics
Published: January 29, 2015
Last Updated: 09/26/2026